January 20, 2011 -- Cambridge Biomedical would like to announce the hiring of the new Chief Operating Officer Dr. John Reddington. Dr. Reddington recently served as President and CEO of Sirtex Medical, Inc., the US division of an Australian publicly traded company. Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease. Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market. Dr. Reddington received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM and PhD from Washington State University.
About Cambridge Biomedical
Cambridge Biomedical is a Boston-based contract laboratory service organization that specializes in analytical testing support of preclinical and Phase I-IV clinical trials. Our laboratory is GLP compliant, CLIA certified, CAP accredited and registered with the FDA. Additional permits allow us to perform clinical diagnostic tests on specimens from all 50 US states.
www.cambridgebiomedical.com
